The Pharma Data

APRIL 4, 2022

Chief Medical Officer and Head of Global Product Development, Roche. More than one million people with severe or critical COVID-19 have already been treated with Actemra/RoActemra worldwide, demonstrating the important role of this medicine in the fight against the pandemic.”. A decision on U.S. Actemra/RoActemra is not U.S.

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials In-Vitro 52

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Dr. Graham earned an M.D.,

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

The Pharma Data

JANUARY 19, 2021

The proceeds will be used to fund its ongoing clinical and preclinical programs. The company is using its pioneering FasTCAR and TruUCAR technology platforms to discover and develop breakthrough cell therapies. Ortho Clinical Diagnostics is a leader in in vitro diagnostics. TCR2 Therapeutics – The Cambridge, Mass.

In-Vitro 52

In-Vitro Production Trials Manufacturing 52

The Pharma Data

MAY 27, 2022

Data from the NP30179 study have been submitted for approval to the European Medicines Agency (EMA), and submissions to additional health authorities worldwide, including to the U.S. Glofitamab is being investigated in several clinical trials and explored in earlier lines of lymphoma treatment. After a median follow-up of 12.6

Antibody 52

Antibody In-Vitro Medicine Engineer 52

The Pharma Data

APRIL 29, 2022

Among the infants with an available assessment (n=48) treated with Evrysdi, 32 infants maintained and four gained the ability to sit without support for at least five seconds since month 24, as assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development Third Edition (BSID-III).

Protein 52

Protein In-Vitro Medicine Development 52

The Pharma Data

MAY 31, 2022

More than 5,000 patients have now been treated worldwide with Evrysdi in clinical trials, compassionate use or real-world settings. Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics. Jude Children’s Research Hospital.

FDA Approval 52

FDA Approval Protein In-Vitro Medicine 52

The Pharma Data

JANUARY 31, 2021

As a first step, Sosei Heptares and Metrion will combine their respective capabilities in a drug discovery program to identify novel, highly specific drug leads for further development against a single ion channel associated with neurological diseases. ” About Sosei Heptares.

Drugs 52

Drugs Protein In-Vitro Development 52

The Pharma Data

SEPTEMBER 19, 2020

Basel, 19 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

HR 52

HR Medicine In-Vitro Development 52

The Pharma Data

SEPTEMBER 2, 2020

Initiation of Phase IIIb OCREVUS higher dose clinical trial programme and Phase IV study evaluating OCREVUS in minority populations. Roche’s Chief Medical Officer and Head of Global Product Development. Roche’s Chief Medical Officer and Head of Global Product Development.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Medicine 52

The Pharma Data

MAY 15, 2023

Roche’s Chief Medical Officer and Head of Global Product Development. The data from the BALATON and COMINO studies will be submitted to other health authorities around the world, including the European Medicines Agency, for approval for the treatment of macular edema following RVO. In BALATON, vision gains were +16.9

Antibody 40

Antibody In-Vitro Clinical Development Medicine 40

The Pharma Data

APRIL 12, 2023

Chief Medical Officer and Head of Global Product Development. Chief Medical Officer and Head of Global Product Development. Chief Medical Officer and Head of Global Product Development. Chief Medical Officer and Head of Global Product Development. “We

Antibody 40

Antibody In-Vitro Development Trials 40

The Pharma Data

DECEMBER 13, 2020

Selected Clinical Parameters in Patients with Type 2 Diabetes at 12 Weeks. Selected Clinical Parameters in Patients with Type 2 Diabetes at 12 Weeks. PXL770 is a first-in-class, oral direct adenosine monophosphate-activated protein kinase (AMPK) activator.

Trials 40

Trials In-Vitro Insulin Protein 40

XTalks

NOVEMBER 19, 2021

Cardiac biomarkers can not only serve important roles in the diagnosis, management and prognosis of cardiac diseases, but they can also be significant tools in evaluating treatments in cardiovascular (CV) clinical trials. In CV clinical trials, cardiac biomarkers are most commonly included in efficacy and safety endpoints.

Clinical Trials 98

Clinical Trials Clinical Trials Trials In-Vitro 98

pharmaphorum

JULY 6, 2022

The JV has been formed German pharma companies Boehringer Ingelheim and Evotec with in vitro diagnostics specialist bioMérieux, with the objective of developing new antimicrobial drugs backed by diagnostics to quickly identify pathogens and their resistance patterns and guide treatment.

In-Vitro 59

In-Vitro Development Pharma Companies Drugs 59

Pharmaceutical Technology

MAY 26, 2023

Doggybone DNA is named for its bone-shaped schematic structure and produced using an in vitro enzymatic process over 50 days, which is more than five times quicker than the 270 days taken for plasmid DNA E.Coli fermentation process. One big pharma company has already given the seal of approval with a successful customer quality audit.

DNA 130

DNA Manufacturing Gene Gene Therapy 130

The Pharma Data

SEPTEMBER 16, 2020

New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Blueprint Medicines will present new data from the registrational phase I/II ARROW trial, investigating Gavreto TM (pralsetinib) for the treatment of people with RET-mutant medullary thyroid cancer.

HR 52

HR Medicine Hormones Trials 52

The Pharma Data

SEPTEMBER 9, 2020

The longer-term data for ENSPRYNG further reinforce the previously observed efficacy of this medicine for this debilitating disorder that is often mistaken for multiple sclerosis,” said Levi Garraway, M.D., Roche’s Chief Medical Officer and Head of Global Product Development. ENSPRYNG was recently approved by the U.S.

Antibody 52

Antibody Medicine In-Vitro HR 52

The Pharma Data

AUGUST 16, 2020

“Today’s FDA approval of ENSPRYNG, the first subcutaneous NMOSD treatment using novel recycling antibody technology, builds upon the work we’ve done in multiple sclerosis with OCREVUS to develop first-in-class medicines and further the scientific understanding of neuroimmunological diseases,” said Levi Garraway, M.D., with placebo.

FDA Approval 52

FDA Approval Antibody Clinical Trials Clinical Trials 52

The Pharma Data

MAY 18, 2021

Chief Medical Officer and Head of Global Product Development. If approved, ENSPRYNG will be the first and only treatment available to both adults and adolescents from 12 years of age with anti-aquaporin-4 antibody (AQP4-IgG) seropositive NMOSD in the EU. Preventing these relapses is the primary goal for disease management.

Antibody 40

Antibody Medicine In-Vitro Development 40

The Pharma Data

APRIL 22, 2023

UC Davis Health researchers have dosed the second participant in their clinical trial looking to identify a potential cure for HIV utilizing CAR T-cell therapy. The trial is the first-in-human clinical study investigating the duoCAR T-cell therapy for the treatment of HIV. The novel study uses immunotherapy.

Clinical Trials 40

Clinical Trials Clinical Trials Trials In-Vitro 40

The Pharma Data

DECEMBER 9, 2020

The new company, created by Hillhouse Capital Venture Partners, launched this week with a mission to pursue the most promising advances in medicine for underserved patients in Asia and around the world. We look forward to developing and advancing our differentiated pipeline of novel therapeutics in carefully selected disease areas.”.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

The Pharma Data

MARCH 17, 2021

This analysis revealed the addition of Verzenio to ET did not result in a clinically meaningful difference in patients reporting being bothered by treatment side effects. The detailed data were presented at the virtual 17th St. Gallen International Breast Cancer Conference. Overall, patient compliance for PROs was greater than 90 percent.

HR 52

HR Trials In-Vitro Manufacturing 52

The Pharma Data

MARCH 29, 2022

Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 2 subvariant, now the dominant strain in Europe. 1-3 Evusheld was generally well-tolerated in the trial. Christoph D.

Antibody 52

Antibody In-Vivo Vaccination Vaccine 52

pharmaphorum

JANUARY 16, 2023

There were developments in the past 12 months, true – Biogen/Eisai’s lecanemab (now branded Leqembi) showed clear success in the Clarity AD trial and received approval by FDA on 6th January 2023. And all are predominantly prevented or treated with medicines that are decades old.

Gene Therapy 98

Gene Therapy In-Vitro Gene Medicine 98

Pharmaceutical Technology

AUGUST 26, 2008

As understanding of biological systems has forged ahead, pharmaceutical companies have made increasing use of biotechnology in discovering and manufacturing new medicines. It was once derided as the stuff of science fiction, but in recent years, biotechnology has emerged as an important growth area in pharmaceuticals.

Antibody 100

Antibody Licensing Licensing Production 100

The Pharma Data

JUNE 26, 2021

Roche’s Chief Medical Officer and Head of Global Product Development. Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. The EUA is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVID-19 in more than 5,500 hospitalised patients.

Clinical Trials 40

Clinical Trials Clinical Trials In-Vitro Antibody 40

The Pharma Data

SEPTEMBER 27, 2020

In addition, at two years, 59% (10/17 vs. 7/17 at 1-year) of infants were able to sit without support for at least 5 seconds, assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development – Third Edition (BSID-III). Roche’s Chief Medical Officer and Head of Global Product Development.

Protein 52

Protein In-Vitro Medicine FDA Approval 52

The Pharma Data

MARCH 26, 2021

Preclinical data suggest VIR-7831 targets a highly conserved epitope of the spike protein, which may make it more difficult for resistance to develop. GSK and Vir will continue discussions with the European Medicines Agency (EMA) and other global regulators to make VIR-7831 available to patients with COVID-19 as soon as possible.

Antibody 52

Antibody Trials Vaccination Vaccine 52

XTalks

JANUARY 6, 2025

This blog highlights the top 10 biotech trends for 2025, showcasing cutting-edge technologies and approaches that promise to redefine patient care, accelerate drug development and expand our understanding of human biology. Related: Biotech IPOs in 2024: Navigating the New Wave of Innovation 1.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111

XTalks

SEPTEMBER 14, 2020

By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. And in truth, the companies the White House picked were pretty savvy as several are current front-runners in the race to develop a vaccine. The price of that prize is incalculable.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92